Phaseline

Companies › Akamis Bio

Akamis Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NG-350A
Tumour-selective anti-CD40-expressing adenoviral vector
CD40Phase 1Locally Advanced Rectal Cancer (LARC)Jan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06459869NG-350APhase 1Locally Advanced Rectal Cancer (LARC)OncologyJan 2027

Targets

CD40 (1)

Companies with the same targets

AbbVie Xencor Genmab RANI Therapeutics Roche Alligator Bioscience Veloxis Pharmaceuticals Novartis

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.